Investigating how ceramides contribute to obesity-related colorectal cancer
Ceramides as novel drivers of metabolic dysfunction and colorectal cancer
This study is looking at how certain fats in the body, called ceramides, might be linked to colorectal cancer in people who are obese, and it aims to find out how diet affects these fats, so we can create better ways to reduce cancer risk.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10910091 on NIH RePORTER |
What this research studies
This research explores the role of ceramides, which are lipids that can signal metabolic dysfunction, in the development of colorectal cancer (CRC) associated with obesity. By analyzing serum samples from large clinical cohorts, the study aims to establish a ceramide-based risk score for CRC and identify dietary patterns that influence ceramide levels. The research employs a combination of epidemiological data and animal experiments to understand how ceramide metabolism affects cancer development and to develop potential dietary and pharmacological interventions. Patients may be involved in providing serum samples and participating in dietary assessments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are obese and at risk for colorectal cancer, particularly those with metabolic dysfunction.
Not a fit: Patients who are not obese or do not have metabolic dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing colorectal cancer in individuals with obesity by targeting ceramide metabolism.
How similar studies have performed: Previous research has shown promising results in understanding the role of metabolic factors in cancer development, making this approach both relevant and potentially impactful.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Playdon, Mary Christine — University of Utah
- Study coordinator: Playdon, Mary Christine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.